Bactolife Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 52

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $35M

  • Investors
  • 7

Bactolife General Information

Description

Developer of proprietary binding protein ingredients designed to fortify the gut microbiome and reduce the risk of gastrointestinal infections in humans and animals. The company's platform focuses on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, it aims to empower worldwide gut health and reduce dependence on antimicrobials to combat antimicrobial resistance, improving human and animal health through their innovative gut microbiome modulation technologies.

Contact Information

Formerly Known As
Bactolife Technologies ApS, Bactolife Biotech ApS, Bactolife Biotherapeutics ApS, Bactolife Biosciences ApS, Bactolife Biologics ApS
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rønnegade 8, 2.
  • 2100 Copenhagen
  • Denmark
+45 53
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Rønnegade 8, 2.
  • 2100 Copenhagen
  • Denmark
+45 53

Bactolife Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bactolife Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 06-Jan-2026 $35M Completed Generating Revenue
5. Later Stage VC (Series A) 08-Aug-2023 Completed Generating Revenue
4. Grant 31-Aug-2022 Completed Generating Revenue
3. Early Stage VC 19-Apr-2021 Completed Generating Revenue
2. Seed Round 01-Jul-2020 $2.02M $2.02M Completed Generating Revenue
1. Grant 01-Jan-2020 $1.64M Completed Generating Revenue
To view Bactolife’s complete valuation and funding history, request access »

Bactolife Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 139,853 $55.33 $55.33 1x $55.33
Ordinary 45,318 $43.93 $43.93 1x $43.93
To view Bactolife’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bactolife Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of proprietary binding protein ingredients designed to fortify the gut microbiome and reduce the risk of gastr
Biotechnology
Copenhagen, Denmark
52 As of 2026

Copenhagen, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bactolife Competitors (1)

One of Bactolife’s competitors is Avilex Pharma, a Venture Capital-Backed company based in Copenhagen, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avilex Pharma Venture Capital-Backed Copenhagen, Denmark
You’re viewing 1 of 1 competitors. Get the full list »

Bactolife Patents

Bactolife Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026185451-A1 Single-domain antibody combined with butyrate for intestinal health improvement Pending 07-Mar-2025
WO-2026131712-A1 Single-domain antibody to reduce the risk of rotavirus a infection Pending 17-Dec-2024
WO-2025228958-A1 Single-domain antibodies to reduce the risk of cholera and e. coli infection Pending 30-Apr-2024
WO-2024121125-A1 Single-domain antibodies to reduce the risk of cholera infection Inactive 06-Dec-2022
EP-4601745-A1 Sdab-cbm fusion protein bound to polysaccharide polymer Pending 14-Oct-2022 C07K16/12
To view Bactolife’s complete patent history, request access »

Bactolife Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bactolife Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cross Border Impact Ventures Impact Investing Minority
Denmark's Export and Investment Fund Venture Capital Minority
Athos (Family Office) Family Office Minority
Gates Foundation Not-For-Profit Venture Capital Minority
Novo Holdings Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Bactolife FAQs

  • When was Bactolife founded?

    Bactolife was founded in 2017.

  • Where is Bactolife headquartered?

    Bactolife is headquartered in Copenhagen, Denmark.

  • What is the size of Bactolife?

    Bactolife has 52 total employees.

  • What industry is Bactolife in?

    Bactolife’s primary industry is Biotechnology.

  • Is Bactolife a private or public company?

    Bactolife is a Private company.

  • What is Bactolife’s current revenue?

    The current revenue for Bactolife is .

  • How much funding has Bactolife raised over time?

    Bactolife has raised $79.1M.

  • Who are Bactolife’s investors?

    Cross Border Impact Ventures, Denmark's Export and Investment Fund, Athos (Family Office), Gates Foundation, and Novo Holdings are 5 of 7 investors who have invested in Bactolife.

  • Who are Bactolife’s competitors?

    Avilex Pharma is a competitor of Bactolife.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process